OpenNashPodcasts

Topic

Roche

Roche is a Swiss healthcare company that appears across podcasts on biotech deals and on healthcare in Asia Pacific. Ahmed Elhusseiny told Analyse Asia with Bernard Leong that it is about 125 years old and has two broad parts, Roche Pharmaceuticals and Roche Diagnostics.

Speakers also discuss its dealmaking. Luke Timmerman said Roche acquired Flatiron Health for $2.1 billion, and a guest on Approved said Blueprint Medicines signed a $775 million partnership with Roche in July 2020. Alex Kesin said Roche returned the Gavreto rights in February 2023 after weak sales. Chris Gibson said Recursion signed a collaboration with Roche and Genentech lasting more than a decade.

16 facts from 5 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

2018

Roche acquired Flatiron Health in February for $2.1 billion, according to host Luke Timmerman.

“Flatiron was acquired by Roche in February for $2.1 billion.”

Luke Timmerman · Ep27: Amy Abernethy, 0:01:14

2018

Flatiron has created internal structures to wall off teams so confidential client information is not disclosed to Roche or other clients.

“We cannot disclose any of that information. In fact, have created internal structures to wall off the teams”

Amy Abernethy · Ep27: Amy Abernethy, 0:52:43

Undated

Recursion signed a collaboration with Roche and Genentech lasting more than a decade, covering neuroscience and one oncology indication.

“In December, almost exactly a year ago, December last year, we signed a huge collaboration with Rosh and Genentech to deploy our technology in partnership with them for more than a decade”

Chris Gibson · AI & Computational Biology With Recursion's Chris Gibson, Ph.D., 0:36:05

Episodes